Antiviral pioneer Gilead Sciences is expected to report fourth-quarter earnings results on Tuesday after the closing bell. A Zacks Rank #3 (Hold) stock, Gilead surpassed earnings estimates in three of the past four quarters. With the stock showing momentum this year, is GILD a buy ahead of the release?
Find the latest EPS estimates and surprises on Zacks Earnings Calendar.
Analysts expect the company to post a profit of $1.83 per share, reflecting a -3.7% decline versus the same quarter in the prior year. Estimates for the quarter have come down slightly over the past 60 days. Revenues are projected to rise 0.07% to $7.57 billion.
The drug developer posted a trailing four-quarter average earnings surprise of 7.8%. Its market-leading HIV franchise has fueled top-line growth. Gilead GILD has also diversified into the lucrative oncology market.
Shares remain undervalued relative to industry peers. The stock is outperforming in 2026 with a 22% return year-to-date.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Gilead Sciences, Inc. (GILD): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
